Zacks Investment Research Lowers Simulations Plus (SLP) to Sell

Simulations Plus (NASDAQ:SLP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

According to Zacks, “Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies. “

Separately, BidaskClub upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th.

Simulations Plus (SLP) opened at $16.95 on Friday. Simulations Plus has a 12-month low of $8.81 and a 12-month high of $17.45. The company has a market cap of $289.52, a PE ratio of 49.26 and a beta of -0.76.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Tuesday, November 14th. The technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.01. The firm had revenue of $6.30 million for the quarter, compared to analyst estimates of $5.01 million. Simulations Plus had a net margin of 23.94% and a return on equity of 23.95%. sell-side analysts predict that Simulations Plus will post 0.39 earnings per share for the current fiscal year.

In other news, major shareholder Walter S. Woltosz sold 18,500 shares of the stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $15.45, for a total value of $285,825.00. Following the completion of the transaction, the insider now directly owns 5,647,916 shares in the company, valued at $87,260,302.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 55,500 shares of company stock valued at $880,600 over the last quarter. Insiders own 36.93% of the company’s stock.

A number of large investors have recently modified their holdings of SLP. William Blair Investment Management LLC boosted its stake in Simulations Plus by 331.9% in the 2nd quarter. William Blair Investment Management LLC now owns 322,614 shares of the technology company’s stock worth $3,984,000 after purchasing an additional 247,926 shares during the period. Northern Trust Corp boosted its stake in Simulations Plus by 248.7% in the 2nd quarter. Northern Trust Corp now owns 145,018 shares of the technology company’s stock worth $1,791,000 after purchasing an additional 103,435 shares during the period. Bessemer Group Inc. boosted its stake in Simulations Plus by 285.7% in the 3rd quarter. Bessemer Group Inc. now owns 29,700 shares of the technology company’s stock worth $460,000 after purchasing an additional 22,000 shares during the period. Bank of New York Mellon Corp acquired a new position in Simulations Plus in the 2nd quarter worth approximately $386,000. Finally, Dimensional Fund Advisors LP boosted its stake in Simulations Plus by 8.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 400,308 shares of the technology company’s stock worth $4,944,000 after purchasing an additional 32,114 shares during the period. Hedge funds and other institutional investors own 33.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Simulations Plus (SLP) to Sell” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/22/zacks-investment-research-lowers-simulations-plus-slp-to-sell.html.

About Simulations Plus

Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit